克罗恩病患者阿达木单抗减量至每3周40mg的剂量降阶梯研究——一项巢式病例对照研究
该巢式病例对照研究纳入40例维持期使用阿达木单抗40mg每3周治疗的克罗恩病患者及性别年龄匹配的对照,减量后4个月内阿达木单抗血清水平显著下降但无临床或生化改变。中位随访24个月时65%患者维持临床应答,35%因临床复发或血清水平不足需恢复每2周给药,减量时CRP<3.5mg/L与无剂量回升生存独立相关(OR 6.28,95%CI 1.83-21.59,P=0.004)。
要点
- 阿达木单抗减量至每3周40mg后4个月内血清水平显著下降但未伴随临床或生化指标变化。
- 中位随访24个月时65%患者维持临床应答,35%因临床复发或血清水平低于4μg/mL需恢复每2周给药。
- 减量时CRP<3.5mg/L与无剂量回升生存独立相关(OR 6.28,95%CI 1.83-21.59,P=0.004)。
核心结论
- 总体上,减量至阿达木单抗40mg每3周的患者中65%在中位24个月内维持临床缓解。
- 53%的患者在减量后阿达木单抗相关不良事件消失。
- 无论阿达木单抗血清水平如何,减量前均应客观评估疾病缓解情况。
- 无法确定可考虑或维持减量的最低阿达木单抗血清水平。
研究设计与样本
- 巢式病例对照研究,从898例患者中筛选出40例(11例男性,中位年龄37岁)维持期使用阿达木单抗40mg每3周且有减量前后血清水平数据的克罗恩病患者。
- 以性别和年龄匹配、继续使用阿达木单抗40mg每2周的患者作为对照。
- 收集患者报告结局、C反应蛋白和血清白蛋白。
主要发现
- 减量原因包括阿达木单抗相关不良事件(n=1)、阿达木单抗血清水平>7μg/mL(n=8)或两者兼有(n=31)。
- 与对照组相比,减量后4个月内阿达木单抗血清水平显著下降,但无相关的临床或生化改变。
- 53%的患者减量后不良事件消失(皮肤表现8/16、关节痛3/6、频繁感染发作5/7)。
- 中位随访24个月,65%的患者维持临床应答,35%需恢复至阿达木单抗40mg每2周(临床复发n=8、阿达木单抗血清水平<4μg/mL n=2、两者兼有n=4)。
- 减量时CRP<3.5mg/L与无剂量回升生存独立相关(OR 6.28,95%CI 1.83-21.59,P=0.004)。
关键数值与推荐
- 减量时CRP<3.5mg/L与无剂量回升生存独立相关(OR 6.28,95%CI 1.83-21.59,P=0.004)。
- 无法确定可考虑或维持减量的最低阿达木单抗血清水平。
临床怎么用
- 无论阿达木单抗血清水平如何,减量前均应客观评估疾病缓解情况。
- 减量后需监测临床复发及阿达木单抗血清水平,必要时恢复至每2周给药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on dose de-escalation in patients with Crohn's disease (CD) are limited. AIM: To evaluate outcomes of dose de-escalation from adalimumab (ADM) every other week (EOW) to every three weeks (ETW). METHODS: We selected patients with CD receiving maintenance therapy with ADM 40 mg ETW with serum levels (SL) available before and after dose de-escalation. Sex- and age-matched controls continuing ADM 40 mg EOW were identified. Patient reported outcome, C-reactive protein (CRP) and serum albumin were collected. RESULTS: Out of 898 patients, we identified 40 (11 male, median 37 years) who de-escalated to ADM 40 mg ETW for ADM-related adverse events (AE, n = 1), ADM SL >7 μg/mL (n = 8), or both (n = 31). Compared to controls, ADM SL dropped significantly within 4 months, without associated clinical or biochemical changes. In 53% of patients, dose de-escalation was associated with disappearance of AE (8/16 skin manifestation, 3/6 arthralgia, 5/7 frequent infectious episodes). During a median follow-up of 24 months, 65% of patients maintained clinical response, but 35% needed dose escalation back to ADM 40 mg EOW because of clinical relapse (n = 8), ADM SL <4 μg/mL (n = 2), or both (n = 4). CRP <3.5 mg/L at dose de-escalation was independently associated with dose escalation-free survival [odds ratio 6.28 (95% CI 1.83-21.59), P = 0.004]. We could not define a minimal ADM SL to consider or maintain dose de-escalation. CONCLUSIONS: Overall, 65% of patients who de-escalated to adalimumab 40 mg every 3 weeks remained in clinical remission for a median of 24 months. In 53% of patients, adalimumab-related adverse events disappeared after dose de-escalation. Regardless of adalimumab SL, disease remission should be assessed objectively prior to dose de-escalation.
引用
- Van Steenbergen S, Bian S, Vermeire S, et al. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study. Aliment Pharmacol Ther. 2017. PMID: 28164321. doi:10.1111/apt.13964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。